Autolus Therapeutics (AUTL) Earnings Date & Reports

Key Takeaways

• Autolus reported third quarter 2026 AUCATZYL net product revenue of $41.2 million, a 95% increase from $21.1 million a year earlier.
• Net loss narrowed to $55.1 million, or $0.21 per share, compared with a loss of $79.1 million, or $0.30 per share, in the prior-year period.
• Gross margin climbed to 57%, up from 55% in the second quarter of 2026 and a sharp improvement from a negative margin a year ago.
• Management raised its full-year 2026 outlook, now expecting AUCATZYL net product revenue at or above the upper end of $150 million.
• Cash, cash equivalents, and marketable securities totaled $248.4 million, with a projected runway into the second quarter of 2028.
• Get more detail on the company's Major News, Today's Price Move, Price Targets, and Forecast.
• Looking for AI-driven trade ideas? Explore Trending AI Robots to see automated strategies at work across the market.

Earnings Context and Why It Matters

Autolus Therapeutics is an early commercial-stage biopharmaceutical company focused on next-generation programmed T cell therapies. Its lead product, AUCATZYL (obecabtagene autoleucel, or obe-cel), is a chimeric antigen receptor T-cell (CAR-T) therapy used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). This quarterly report matters because it measures whether a young, high-cost product launch can translate early revenue growth into improving margins. Investors are watching gross margin progression, cash burn, and the pace of treatment-center expansion, all of which signal whether Autolus can move toward a self-sustaining commercial franchise while funding a pipeline that extends into lupus, multiple sclerosis, and pediatric leukemia.

Reported Results

Autolus reported third quarter 2026 AUCATZYL net product revenue of $41.2 million, up 95% year over year and slightly ahead of consensus estimates. Net loss narrowed to $55.1 million from $79.1 million a year earlier, translating to a basic and diluted net loss of $0.21 per ordinary share versus $0.30 in the third quarter of 2025.

The most notable improvement came in profitability. Gross margin reached 57%, up from 55% in the second quarter and a dramatic swing from a negative margin a year earlier, driven by higher production volumes, lower manufacturing cost per batch, and smaller inventory write-offs. Research and development expense was $30.9 million, while selling, general, and administrative expense was $35.9 million.

Management also raised guidance, now expecting full-year 2026 AUCATZYL net product revenue at or above the upper end of $150 million, marking a third consecutive upgrade from an original range of $120 million to $135 million. The company ended the quarter with $248.4 million in cash, cash equivalents, and marketable securities, supported by a credit facility executed earlier in the year.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following names like Autolus Therapeutics and the broader biotechnology space, it offers a structured way to monitor momentum and identify setups as they develop.

Market Reaction and Investor Sentiment

Reaction to the report reflected a mixed picture. The top line exceeded consensus expectations and margins continued their sharp upward trajectory, reinforcing confidence in the AUCATZYL launch. However, revenue declined sequentially from $45.7 million in the second quarter, and management framed the softness as part of a seasonal pattern rather than a demand problem, noting that holiday dynamics and the timing of patient infusions can shift sales between quarters. A delayed readout for the progressive multiple sclerosis program, now expected at ECTRIMS in October 2027, also tempered enthusiasm. Heading into the report, sentiment was cautious, and investors weighed the improving profitability profile against questions about when sequential sales growth would resume.

Forward Outlook and Key Factors to Monitor

Several themes will shape how investors evaluate Autolus in the coming quarters. First, the trajectory of AUCATZYL revenue remains central. Management expanded U.S. treatment centers to 90 and added 18 in the U.K., and deeper use within existing centers is now the primary growth driver. Whether that breadth converts into renewed sequential growth will be closely watched.

Second, the margin story is strengthening but not complete. Gross margin of 57% still has room to rise toward management's longer-term target, and cost discipline across manufacturing and operations will determine how quickly losses narrow further.

Third, the pipeline carries meaningful catalysts. Upcoming data presentations at ASH (American Society of Hematology) are expected to include additional ALL data and the first data for AUTO8 in light-chain amyloidosis. The CARLYSLE study in severe refractory systemic lupus erythematosus (SLE) is also generating longer-term follow-up. Meanwhile, the delayed progressive multiple sclerosis readout shifts one key milestone into late 2027.

Finally, the balance sheet provides runway into the second quarter of 2028, but continued cash use in operating activities means capital efficiency will remain a focus. Investors will monitor these signals without any assurance of future performance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations